CD4 and glioma: In this study, we demonstrated that PC61 anti-CD25 mAb treatment of glioma bearing mice resulted in a decrease of brain-infiltrating Tregs only, whereas the CD4+ and CD8+ effector cells were increased and could exert their cytotoxic activity on the tumor cells.